ADC Therapeutics $200 million at-the-market offering We advised ADC Therapeutics on the offering of shares

Davis Polk advised ADC Therapeutics SA in connection with its SEC-registered at-the-market offering of its common shares for up to an aggregate amount of $200 million. The common shares are listed on the New York Stock Exchange under the symbol 'ADCT.'

ADC Therapeutics is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs). The company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics' CD19-directed ADC ZYNLONTA is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in late-stage clinical trials in combination with other agents. Cami is being evaluated in a late-stage clinical trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, the company has multiple PBD-based ADCs in ongoing clinical and preclinical development.

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates David Li and Jakub P. Jozwiak. Partner Michael Farber provided tax advice. All members of the Davis Polk team are based in the New York office.